


# An Alternate Pathway of Arsenate Resistance in *E. coli* Mediated by the Glutathione S-Transferase GstB

Constantine Chrysostomou,<sup>†</sup> Erik M. Quandt,<sup>§</sup> Nicholas M. Marshall,<sup>†</sup> Everett Stone,<sup>‡</sup> and George Georgiou<sup>\*,†,‡,§</sup>

Departments of <sup>†</sup>Chemical Engineering and <sup>‡</sup>Biomedical Engineering, and <sup>§</sup>Molecular Genetics and Microbiology and Institute for Cell and Molecular Biology, University of Texas, Austin, Texas 78712, United States

## S Supporting Information

**ABSTRACT:** Microbial arsenate resistance is known to be conferred by specialized oxidoreductase enzymes termed arsenate reductases. We carried out a genetic selection on media supplemented with sodium arsenate for multicopy genes that can confer growth to *E. coli* mutant cells lacking the gene for arsenate reductase (*E. coli*  $\Delta$ arsC). We found that overexpression of glutathione S-transferase B (GstB) complemented the  $\Delta$ arsC allele and conferred growth on media containing up to 5 mM sodium arsenate. Interestingly, unlike wild type *E. coli* arsenate reductase, arsenate resistance via GstB was not dependent on reducing equivalents provided by glutaredoxins or a catalytic cysteine residue. Instead, two arginine residues, which presumably coordinate the arsenate substrate within the electrophilic binding site of GstB, were found to be critical for transferase activity. We provide biochemical evidence that GstB acts to directly reduce arsenate to arsenite with reduced glutathione (GSH) as the electron donor. Our results reveal a pathway for the detoxification of arsenate in bacteria that hinges on a previously undescribed function of a bacterial glutathione S-transferase.



In nature, the toxic heavy metalloid, arsenic, exists predominately as oxyanions in either its pentavalent (arsenate,  $\text{H}_2\text{AsO}_4^{1-}$ ) or trivalent oxidation states (arsenite,  $\text{H}_3\text{AsO}_3$ ).<sup>1</sup> The natural abundance of both toxic species imposes a strong selection pressure for organisms to evolve arsenic detoxification pathways.<sup>1,2</sup> Detoxification of arsenite is achieved via sequestration or efflux from arsenite specific transporters.<sup>3,4</sup> Arsenate, on the other hand, is commonly exported only after reduction to arsenite.<sup>1,5,6</sup> This reductive step is catalyzed by a diverse class of enzymes termed arsenate reductases.<sup>1</sup>

Arsenate resistance seems to be a highly plastic process in which organisms can utilize a variety of pathways to perform the necessary reduction reaction. Five mechanistically and phylogenetically distinct classes of arsenate reductase enzymes have been identified so far.<sup>1</sup> While all families contain a catalytic redox-sensitive cysteine (Cys) residue, the specific mechanism of action can differ significantly between classes.<sup>1</sup> Arsenate reductases from Gram-positive bacteria accept electrons from thioredoxins, which are maintained in the reduced state by the NADPH-dependent enzyme thioredoxin reductase.<sup>7</sup> These enzymes display structural similarity to mammalian tyrosine phosphatase enzymes and exhibit phosphatase activity *in vitro*.<sup>8,9</sup> Conversely, arsenate reductases from Gram-negative bacteria, including *E. coli*, depend on the glutathione/glutaredoxin reductive pathway.<sup>10,11</sup> This class of reductases does not exhibit phosphatase activity.<sup>12</sup> The yeast *S. cerevisiae* protein, ACR2p, represents the third class of arsenate

reductases. This eukaryotic class of enzymes is also dependent on reducing equivalents provided by glutaredoxin and glutathione,<sup>13</sup> but its active site is related to a different class of protein tyrosine phosphatases.<sup>14</sup> A fourth class has been identified in cyanobacteria, which express a glutaredoxin-dependent reductase enzyme with structural similarity to the thioredoxin class of reductases.<sup>15</sup> Finally, a fifth and unique class of reductive enzymes is part of anaerobic respiration in various Gram-positive and negative bacterial species, such as Gram-negative *C. arsenatis*, which utilize arsenate, rather than oxygen, as the terminal electron acceptor during respiration.<sup>16</sup>

In an earlier study, we used a genetic selection to identify alternate electron transfer pathways for the reduction of arsenate in *E. coli*. Selection for suppressor mutations capable of rescuing arsenate sensitivity in a glutathione (GSH) null *E. coli* mutant ( $\Delta$ gshA) revealed an evolved pathway for glutathione synthesis via the *proAB* operon responsible for proline biosynthesis.<sup>17</sup> Suppressor mutations identified in the *proAB* genes restored electron transfer toward arsenate reduction by accumulating  $\gamma$ -glutamyl phosphate, which reacted spontaneously with L-cysteine to form  $\gamma$ -glutamyl cysteine, the reaction product for GshA.<sup>17</sup> These findings underscored the necessity for the glutaredoxin/glutathione system in providing

Received: September 21, 2014

Accepted: December 17, 2014


Published: December 17, 2014

reducing equivalents for arsenate reduction by the ArsC arsenate reductase.

Here, we asked whether *E. coli* encodes additional pathways capable of conferring resistance to lethal concentrations of arsenate. Using the ASKA library,<sup>18–20</sup> we selected for genes that, upon multicopy expression, allow for growth of arsenate reductase null mutants (*E. coli*  $\Delta$ arsC) in media containing millimolar levels of arsenate. Surprisingly, we found that overexpression of the *gstB* gene, which encodes for the glutathione S-transferase GstB, conferred a high level of arsenate resistance. GstB was previously shown to be involved in bromoacetate resistance via a dehalogenation mechanism in which the conjugation of bromoacetate and glutathione results in the release of a free bromide and formation of glutathione S-acetate.<sup>21</sup> In this study, *in vitro* and *in vivo* biochemical analysis further revealed that, independently of glutaredoxins, GstB can directly facilitate the reduction of arsenate with only GSH as the reductant. While the beta class *E. coli* glutathione S-transferase enzyme (GST), encoded by the gene *gstA*, contains a catalytic cysteine residue essential for its reductive activity,<sup>22</sup> we found that neither of the cysteine residues found in *E. coli* GstB is required for arsenate resistance. Instead, arginine residues near the GSH binding site of GstB are critical for imparting resistance against both arsenate and bromoacetate. Thus, our results define an auxiliary mechanism for arsenate resistance in *E. coli*.

## RESULTS AND DISCUSSION

**GstB Confers Arsenate Resistance to *E. coli* in an ArsC Null Background.** EQ217, an *arsC* null derivative of *E. coli* strain DH10B was created and found to be hypersensitive to arsenate with complete colony growth inhibition observed on MOPS minimal media agar plates containing 0.4 mM sodium arsenate ( $\text{NaH}_2\text{AsO}_4$ ). EQ217 was then transformed with the ASKA library<sup>18</sup> and transformants were plated on MOPS minimal media agar plates with 0.4 mM sodium arsenate and 0.1 mM IPTG to induce protein expression from the ASKA plasmids. Several colonies of varied size arose after 2 days of incubation at 37 °C. Sequencing revealed that all large colonies selected from the screen contained ASKA plasmids bearing the *E. coli* *arsC* gene. The majority of the smaller colonies contained plasmids bearing the *gstB* gene, which encodes for the glutathione S-transferase enzyme GstB. Additionally, we found three resistant clones, which contained plasmids encoding for colonic acid biosynthesis protein, CpsB, and the transcription factors *dk*sA and *fru*R. To confirm that arsenate resistance was conferred by the respective ASKA plasmids, plasmid DNA was isolated and retransformed into cells carrying the  $\Delta$ arsC allele in a different genetic background (*E. coli* DHB4  $\Delta$ arsC, strain EQ279). Resistance phenotypes were again measured on MOPS plates containing sodium arsenate. Among the four genes identified in the screen, multicopy expression of *dk*sA showed a mild increase in resistance to sodium arsenate as compared to the parent strain EQ279 (Supporting Information Figure 1). Only multicopy expression of *gstB* could confer growth on MOPS plates containing more than 1 mM sodium arsenate (Figure 1a). Further analysis showed that *E. coli* EQ279 cells transformed with the plasmid pGstB formed good size colonies on plates containing up to 3 mM sodium arsenate and even formed small colonies on plates containing 5 mM sodium arsenate (Figure 1b). Notably, neither ArsC nor GstB expression could mediate growth of the glutathione null strain WP758 (DHB4  $\Delta$ gshA) in media



**Figure 1.** GstB overexpression confers arsenate resistance to *E. coli*  $\Delta$ arsC cells. (a) Arsenate resistance of DHB4  $\Delta$ arsC cells expressing *gstB*, *cpsB*, *dk*sA, and *fru*R selected from the genetic screen. Strains are plated on MOPS agar plates containing 1 mM sodium arsenate. (b) Growth of varied selected mutant strains expressing either the *gstB* construct (pGstB) or the ASKA *arsC* construct (pArsC<sub>ASKA</sub>). Mutants were grown for 24 h on MOPS plates containing between 0 and 5 mM sodium arsenate. DHB4  $\Delta$ arsC $\Delta$ grxABC represents mutants lacking the *arsC* gene and the glutaredoxin genes *grxA*, *grxB*, and *grxC*;  $\Delta$ arsRBC represents mutants lacking the *arsRBC* operon.

containing more than 0.1 mM sodium arsenate (data not shown). The inability to rescue growth in WP758 indicates that both arsenate resistance mechanisms are dependent upon the presence of intracellular glutathione.


The catalytic cycle of ArsC is known to be dependent on glutaredoxins for reduction.<sup>10</sup> At concentrations above 0.1 mM sodium arsenate, the *Δ*arsC *E. coli* mutant, CC109, carrying three additional deletions of glutaredoxins A, B, and C, showed increased sensitivity to arsenate relative to the parental strain EQ279 (DHB4  $\Delta$ arsC) (Figure 1b). Transformation of mutant strain CC109 with a plasmid encoding ArsC could not restore healthy growth on plates containing low millimolar concentrations of arsenate. In contrast, CC109 cells transformed with a plasmid encoding GstB could grow in the presence of media containing of up to 3 mM sodium arsenate. Thus, unlike arsenate reductase, resistance to arsenate by GstB is not dependent on the expression of the *E. coli* glutaredoxins.

ArsC and ArsB together with the trans-acting repressor ArsR comprise the arsenate resistance operon *arsRBC*. ArsC reduces

arsenate to arsenite, which is then exported from the cell by the ArsB transporter.<sup>4</sup> A DHB4 derived strain containing a complete deletion of the *arsRBC* operon, CC112, could not grow on plates containing more than 0.3 mM sodium arsenate. Moreover, arsenate sensitivity of CC112 could not be rescued by multicopy expression of ArsC or by GstB (Figure 1b). Considering that GstB can rescue bacterial growth of a  $\Delta$ *arsC* mutant and that ArsR is a transcription factor responsible for regulating ArsC and ArsB transcription, the data from Figure 1b indicates that ArsB expression from the *arsRBC* operon is critical for arsenate detoxification by GstB.

**GstB Residues Involved in Arsenate Reduction.** A common feature in redox regulation is the presence of a CXXC motif in the catalytic site of redox sensitive proteins such as *E. coli* glutaredoxins and thioredoxins. The N-terminal and C-terminal cysteine residues within this motif reversibly form disulfide bonds and, depending upon the amino acids between the cysteine pair, are involved in a range of redox reactions.<sup>23,24</sup> *E. coli* GstB also contains the canonical thioredoxin-like CXXC motif comprising cysteine residues C134 and C137. To delineate a role of the cysteine residues in arsenate resistance, we constructed a variant of the *E. coli* GstB enzyme in which both Cys residues in the CXXC motif had been mutated to alanine. Cells expressing GstB<sub>C134A/C137A</sub> from the multicopy plasmid were fully resistant to arsenate and grew in the presence of 1 mM sodium arsenate with a doubling time of  $200 \pm 10$  min compared to  $205 \pm 10$  min for cells expressing wild type GstB (Figure 2 and Supporting Information Figure 2). The observed CXXC motif is not conserved across GstB homologues. *Salmonella enterica* encode for a GstB homologue, YliJ, which displays 83% amino acid identity with *E. coli* GstB but does not contain the N-terminal cysteine residue, C134. Moreover, the crystal structure of *S. enterica* YliJ (PDB 4KH7)<sup>25</sup> suggests that the conserved cysteine residue, C137, is too distant from both the GSH binding site and the putative electrophilic binding site (20–25 Å) to be directly involved in a catalytic mechanism involving glutathione (Figure 2a).

The YliJ crystal structure also indicated that three arginine (Arg) residues common to both GstB and YliJ form a patch of positive charge in close proximity (7 Å) to the glutathione binding site. Closer inspection of the crystal structure suggested that R7 may be directly involved in glutathione binding. Therefore, we chose to focus on the role of arginine residues, R111 and R119, which might be important for positioning anions such as arsenate in close proximity to the nucleophilic thiol of GSH. Substitution of either R111 or R119 for a glutamine residue in the *E. coli* GstB amino acid sequence impaired GstB conferred arsenate resistance. Notably, cells expressing the latter variant, GstB<sub>R119Q</sub> were most sensitive to sodium arsenate and could not grow in media containing more than 2 mM sodium arsenate (Supporting Information Figure 3). Substitution of both Arg residues from GstB, GstB<sub>R111Q/R119Q</sub> completely abolished the ability of GstB to confer arsenate resistance to *E. coli* EQ301 (DHB4  $\Delta$ *arsC* $\Delta$ *gstB*) cells (Figure 2 and Supporting Information Figure 2). To rule out the possibility that the R111Q/R119Q substitutions might have affected the expression or stability of the enzyme rather than having a direct effect on catalysis, we expressed and purified GstB and GstB<sub>R111Q/R119Q</sub> to near homogeneity. GstB and GstB<sub>R111Q/R119Q</sub> displayed identical elution on size exclusion chromatography demonstrating that these two mutations did not result in protein aggregation or denaturation (Supporting Information Figure 4). Differential



**Figure 2.** Mutational analysis of GstB residues involved in arsenate resistance. (a) Crystal structure of the *E. coli* GstB homologue, YliJ, from *Salmonella enterica* (PDB 4KH7). Three arginine residues (blue stick models), R7, R111, and R119, form the putative electrophilic binding site near glutathione (GSH). (b) Growth curves of *E. coli* EQ301 (DHB4  $\Delta$ *arsC* $\Delta$ *gstB*) expressing selected GstB variants from the multicopy pCA24N construct in liquid minimal MOPS media containing either 0 mM sodium arsenate (top panel) or 1 mM sodium arsenate (bottom panel). Growth curves are plotted as the average absorbance values from three independent growth studies. Error bars represent the standard deviation in absorbance at each time point.

scanning fluorometry also revealed that the GstB<sub>R111Q/R119Q</sub> mutant exhibits a slightly increased stability to thermal unfolding ( $47 \pm 0.2$  °C) relative to the wild type enzyme




( $44 \pm 0.4$  °C) (Supporting Information Figure 5). Substitution of residues R111 and R119 was shown not only to abolish the enzyme's ability to mediate resistance to arsenate but also its activity toward other electrophilic substrates. Earlier studies established that GstB can dehalogenate bromoacetate.<sup>21</sup> Unlike the wild type GstB, GstB<sub>R111Q/R119Q</sub> showed no activity with respect to glutathione S-acetate formation (Supporting Information Figure 6). This loss of activity indicates that the two Arg residues are involved in the reactivity of GstB toward electrophilic substrates.

### GstB Catalyzes the Reduction of Arsenate to Arsenite.

The finding that GstB does not confer arsenate resistance in *E. coli* cells lacking the ArsB arsenite transporter, suggests that GstB overexpression may facilitate arsenate reduction to arsenite. To further investigate this hypothesis, we used a two-step assay to detect the accumulation of arsenite in biological mixtures such as culture supernatants or cell lysates. First, arsenite is separated from arsenate in solution by anion exchange chromatography on a silica based resin (Phenomenex Strata SAX columns) at a pH above 3. Arsenate, which is negatively charged at pH > 2.2, stays bound to the column whereas neutral arsenite, not retained by the resin, elutes in the flow through. Arsenite collected from the flow through can be detected using a colorimetric assay in which all arsenic species are first reduced into arsine gas within an enclosed compartment. The formation of arsine gas reacts with mercuric bromide adsorbed onto strip paper and results in a mixed arsenic–mercury halogenide that discolors the test strip proportionally to the concentration of total arsenic in solution.<sup>26</sup> We first established that by using the combination of ion exchange chromatography together with colorimetric detection of arsenic eluted from the column flow-through, we could semi-quantitatively measure between 0.05 and 0.5 mM arsenite in 3–5 mL of growth media containing 50 mM sodium arsenate (Supporting Information Figure 7).

We used the method described above to detect secreted arsenite that had accumulated in the culture supernatants of cells incubated with 1 mM sodium arsenate. For the *in vivo* assay, sodium arsenate was added to the media 1 h after enzyme induction by 0.1 mM IPTG. The degree of arsenite accumulation in the supernatant was determined after a subsequent hour of incubation with arsenate (Figure 3). No arsenite was detected in the *E. coli*  $\Delta gshA$  strain, WP758, which is incapable of synthesizing the reductant GSH. A very low level of arsenite was detected in the supernatant of *E. coli*  $\Delta arsC$  (strain EQ279). The formation of arsenite in EQ279 cells, as opposed to the  $\Delta gshA$  mutant strain, WP758, is most likely due to nonenzymatic reduction of arsenate by intracellular GSH.<sup>27</sup> This observation is consistent with the fact that EQ279 can grow on plates containing low concentrations of sodium arsenate (<0.4 mM) whereas the growth of  $\Delta gshA$  cells (*E. coli* WP758) was inhibited even in the presence of 0.1 mM sodium arsenate.

While DHB4 cells accumulated low levels of arsenite in the culture media, induced expression of ArsC prior to the addition of sodium arsenate resulted in a much higher level of arsenite (Figure 3, Panel 4). This result suggests that the catalytic activity of arsenate reductase expressed by the chromosomal *arsC* gene is rate-limiting. Cells expressing GstB from the pGstB construct also accumulated high levels of arsenite indicating that enzyme plays a direct role in the reduction of arsenate (Figure 3, Panel 6). We note that overexpression of the better characterized *E. coli* glutathione S-transferase, Gst,



**Figure 3.** GstB overexpression results in the accumulation of arsenite in culture supernatant. Levels of arsenite accumulated in the supernatant of bacteria cultured in MOPS minimal media containing 1 mM sodium arsenate were measured using a two-step colorimetric assay. Exported arsenite was isolated from arsenate in the media using anion exchange. Separated arsenite was subsequently detected using a colorimetric assay with mercuric bromide. Panels 1–6 illustrate the levels of arsenite produced by selected *E. coli* mutant strains containing either no plasmid (–), the ASKA *arsC* construct (pArsC<sub>ASKA</sub>), the *gstB* construct (pGstB), or the ASKA *gstA* construct (pGst<sub>ASKA</sub>). Panel 7 represents the detection of arsenic in uninoculated growth media containing only 1 mM sodium arsenate.


did not result in significant arsenite accumulation or increased resistance of *E. coli* EQ279 to arsenate (Figure 3, Panel 5).

We next sought to evaluate whether GstB directly catalyzes the reduction of arsenate *in vitro*. First, purified GstB was incubated with 1 mM GSH and 50 mM sodium arsenate for either 30 or 60 min. The accumulation of arsenite was directly measured by the assay described above. As expected, incubation with wild type GstB resulted in a significant increase in the level of arsenite accumulation over the background rate due to the direct reaction of arsenate with GSH (Figure 4a). In addition, the rate of arsenate reduction by GstB was monitored by measuring the oxidation of NADPH in a redox coupled assay containing NADPH, glutathione reductase (GOR), GSH, and sodium arsenate.<sup>11</sup> With respect to wild type arsenate resistance, glutaredoxins are required to reduce the intermediate ArsC–arsenate–glutathione complex formed and thereby complete the redox cycle.<sup>11</sup> In contrast to the ArsC catalyzed mechanism, addition of purified Glutaredoxin 2 (Grx2) in the reaction above, did not appreciably increase *in vitro* GstB activity by a significant degree (Supporting Information Figure 8). Maintaining the concentration of sodium arsenate at 50 mM while varying the concentration of GSH from 0.1 to 5 mM showed that the rate of GSH oxidation increased linearly at a rate of  $0.02 \text{ (min}^*[\text{GSH mM}])^{-1}$ . Similarly, varying the concentration of sodium arsenate from 20 to 100 mM in a reaction containing 1 mM GSH showed that NADPH oxidation increased linearly at a rate of  $5.6 \times 10^{-4} \text{ (min}^*[\text{sodium arsenate mM}])^{-1}$  (Supporting Information Figure 9). We found that, presumably due to high salt concentration, the reaction rate of arsenate reduction decreased when GstB was incubated with more than 100 mM sodium arsenate and 1 mM GSH. The maximum observed rate was  $0.11 \text{ (min}^*[\text{GSH mM}])^{-1}$  at 5 mM GSH and 50 mM arsenate with 0.12 mM GstB. Finally, the inactive variant GstB<sub>R111Q/R119Q</sub> showed no appreciable increase in arsenite concentration or NADPH oxidation as compared to the noncatalyzed reactions (Figure 4a and b).

## DISCUSSION

Using a genetic selection to identify suppressors of arsenate sensitivity in *E. coli*  $\Delta arsC$  cells, we identified a glutathione S-



**Scheme 1. Proposed Mechanisms of Arsenate Reduction by GstB<sup>a</sup>**

<sup>a</sup>Route A. GstB directly enhances the rate of GS-arsenate conjugation. Once formed, the intermediate undergoes a spontaneous reaction with a second equivalent of GSH, which results in reduction to arsenite and oxidized GSH (GSSG). Route B. Conjugation of one reduced GSH molecule to arsenate occurs spontaneously in solution. The presence of GstB then catalyzes the conjugation of a second GSH molecule to arsenate and subsequent reduction of (GS)<sub>2</sub>-arsenate intermediate into oxidized GSSG and arsenite.

arsenate to form an arsenate–glutathione intermediate that is then reduced by a second GSH molecule in close proximity or in solution. An alternate mechanism assumes that first, GSH spontaneously conjugates to arsenate in solution resulting in a GSH–arsenate complex. Then, GstB catalyzes the rate-limiting step whereby a second glutathione molecule is conjugated to the intermediate complex. We believe that the former mechanism is more plausible for two reasons: first, steric restrictions around the putative GSH binding site of GstB would hinder the ability of a preformed GSH–arsenate complex to interact with a second glutathione equivalent bound to GstB; second, a nonenzymatic arsenate–GSH complex could not be detected *in vitro* by NMR.<sup>27</sup> The inability to detect this intermediate implies that the formation of an arsenate–GSH complex is rate-limiting and that the reduction of arsenate following an interaction with a second GSH equivalent would be rapid. Therefore, it seems more plausible that GstB catalyzes the formation of an initial arsenate–GSH conjugate, which then encounters a second equivalent of GSH, resulting in the reduction of arsenate to arsenite. Collectively our results provide evidence for a mechanistically novel pathway for arsenate detoxification in bacteria involving the glutathione S-transferase enzyme, GstB.

## METHODS

**Reagents.** Sodium arsenate hepta-hydrate (S9663-50G), sodium arsenite (S225I-100G), MOPS salts (M1254-250G), reduced nicotinamide adenine dinucleotide phosphate (NADPH N7505-25MG), and glutathione reductase (GOR) from Baker's Yeast (060M7405) were purchased from Sigma-Aldrich. Disposable Strata-SAX anion-exchange columns (8B-S008-HCH) were purchased from Phenomenex. Isopropyl β-D-1-thiogalactopyranoside (206-703-0), sodium chloride (S640-500), and imidazole (AC39674-5000) were purchased from Fisher Scientific. All reagents for arsenic detection (EZ Arsenic Test Kit Catalog #280000) including arsenic test strips, zinc sulfate, and phosphate were purchased from Hach Chemicals.

**Bacterial Strains, Plasmids, and Media.** Cells challenged for arsenate resistance were grown in MOPS minimal growth media, which contains minimal levels of phosphate.<sup>37</sup> MOPS growth media consisted of MOPS salts, 0.2% casein amino acids, 0.2% glucose, and 1.32 mM KH<sub>2</sub>PO<sub>4</sub>. When necessary, chloramphenicol and/or kanamycin were added to the growth media at a concentration of 33 μg mL<sup>-1</sup> and 25 μg mL<sup>-1</sup>, respectively. To induce gene expression

from the pCA24N constructs (ASKA plasmids), IPTG was added to growth media at a concentration of 0.1 mM. For protein purification, cell strains were grown in 2xYT rich media containing 33 μg mL<sup>-1</sup> of chloramphenicol. The details for all *E. coli* strains are described in Supporting Information Table 1. Briefly, the *arsC* gene from the *E. coli* DH10B derivative strain, Jude 1, and the *E. coli* DHB4 strain was replaced with a kanamycin resistance marker derived from plasmid pKD4 using the Wanner gene knockout method.<sup>38</sup> For each subsequent gene knockout, the kanamycin resistance marker was first removed using FRT recombinase encoded on the pCP20 plasmid.<sup>38</sup> The *E. coli* gene *gstB* was also knocked out of strain EQ279 yielding the mutant strain EQ301 (Δ*arsC*Δ*gstB*). Finally, DHB4 mutants containing knockouts of the individual glutaredoxin genes (*grxA*, *grxB*, and *grxC*) were constructed using P1 transduction<sup>39</sup> of the mutated alleles from donor strains obtained from the Keio Collection.<sup>40</sup> The *arsC* gene was also removed from the mutant strain DHB4Δ*grxA*Δ*grxB*Δ*grxC* (strain CC105), which yielded mutant strain CC109. The *arsRBC* operon was removed from *E. coli* DHB4 using the Wanner method (strain CC112).

The details for all *E. coli* constructs are described in Supporting Information Table 2. Genetic selection was performed using the library of ASKA clones where the GFP tag had been previously removed, leaving behind a C-terminal peptide scar sequence of GLCGR. After the *gstB* gene, encoded by the pCA24N ASKA construct (pGstB<sub>ASKA</sub>), was identified from the genetic screen, the scar sequence was removed from the C-terminal end using quick change PCR (construct pGstB). Select point mutations to the CXXC motif in pGstB (C134A, C137A, and C134A/C137A) and to the putative electrophilic binding pocket (R111Q, R119Q, R111Q/R119Q) were also made using the quick change mutagenesis protocol. A g-block of the GstB homologue gene, *yljI*, was ordered from Integrated DNA Technologies and was subsequently cloned into pCA24N using the Gibson cloning method (construct pGstB<sub>YljI-S.enterica</sub>).

**Genetic Selection.** The electrocompetent *E. coli* Δ*arsC* mutant strain, EQ217, was transformed with the ASKA library. Transformed cells were recovered in LB media containing 0.1 mM IPTG for 2 h. After recovery, cells were plated on MOPS agar plates containing chloramphenicol, kanamycin, 0.4 mM sodium arsenate, and 0.1 mM IPTG. Plates containing colonies were incubated for 2 days at 37 °C. After 2 days, colonies were selected and their corresponding pCA24N constructs from the ASKA library were isolated and sequenced.

**Measurement of Arsenite in Solution.** Solutions of arsenite were separated from arsenate using disposable Strata SAX anion exchange columns from Phenomenex. Arsenate, which is negatively charged at a pH > 2.2, binds to the positively charged column, whereas arsenite, which is uncharged at pH < 9.2, will not bind to the column. Therefore, when a solution containing a mixture of arsenate and arsenite is passed through the column, purified arsenite can be collected in the flow through. The following steps were performed to separate arsenite from arsenate using anion exchange. First, the SAX anion exchange columns were pretreated with 6 mL of methanol followed by 6 mL of 25 mM Tris-OAc buffer (pH 8). Next, 3–6 mL of sample was applied to the column and the flow through was collected. The levels of arsenite in the flow through can then be semiquantitated using the EZ arsenic detection kit provided by Hach chemicals. This kit reportedly detects levels of arsenic as low as 10 ppb in 50 mL water or 35 ppb in 10 mL water. Total arsenic is detected by the zinc catalyzed reduction of arsenite to arsine gas, which is then captured by mercuric bromide strips causing a color change. Strips that appear dark orange/black indicate levels of arsenic above 500 ppb in 50 mL water or 4000 ppb in 10 mL water.

**Measurement of Arsenite Accumulation *In Vivo*.** Cell strains grown overnight were subcultured at a dilution of 1:100 at 37 °C in MOPS media supplemented with appropriate antibiotics for strains containing kanamycin and/or chromosomal resistance markers and plasmids. When cell cultures reached an OD<sub>600</sub> of 0.3, IPTG was added to the growth media to a final concentration of 0.1 mM and allowed to express protein until attaining an OD<sub>600</sub> of 0.6–0.8 (approximately 1 h). After induction, 1 mM sodium arsenate (final concentration) was added to each strain and growth was continued for



1 h. After 1 h of growth, all cell strains were normalized to the same OD, and the supernatant was taken from 5 mL of pelleted cell cultures. As described above, arsenite present in the 5 mL solution was separated from arsenate using the disposable anion exchange columns; the flow through was diluted to 10 mL using water and the amount of arsenite present in each sample was measured using mercuric bromide strips.

**In Vitro Arsenate Reduction.** The reaction buffer for *in vitro* arsenate reduction was 100 mM HEPES at neutral pH 7. In the noncatalyzed reaction, 1 mM of GSH was incubated with 50 mM sodium arsenate. For the enzyme catalyzed reaction, purified enzyme was added to the mixture at a final concentration of 0.12 mM. The total reaction volume was 500  $\mu$ L. After 30 min of incubation, arsenite production was measured using half of the reaction mixture; after 60 min, arsenite production was measured using the remaining solution. At each time point, the pH of the reaction mixture was lowered to 4, diluted to 3 mL, and subsequently separated using the anion exchange columns. The reaction mixture was lowered to pH 4 to separate any arsenite–GSH conjugates known to freely form in solution. The column flow through was diluted to a volume of 10 mL using water before arsenic detection. Arsenite in each reaction mixture was semiquantitated using the arsenite detection assay described above.

## ■ ASSOCIATED CONTENT

### ■ Supporting Information

*E. coli* strains and plasmids used in this study. Survival in the presence of sodium arsenate of *E. coli* EQ279 mutants expressing plasmids isolated from the genetic screen; doubling time of *E. coli* EQ301 mutant strain expressing selected GstB variants; growth in liquid media of *E. coli* EQ301 mutants expressing GstB variants containing point mutations in either the Arg111 and/or Arg119 residue; size exclusion analysis of purified GstB enzymes; differential scanning fluorimetry analysis of purified GstB enzymes; analysis of GstB activity with respect to the conversion of bromoacetate into glutathione S-acetate; two-step semi-quantitative assay for measuring arsenite in solution; comparison of *in vitro* GstB activity with respect to arsenate reduction with and without the addition of purified Glutaredoxin 2; *in vitro* assay for GstB catalyzed arsenate reduction using NADPH redox-coupled assays; supplemental methods. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*Phone: 512-471-6975. E-mail: [gg@che.utexas.edu](mailto:gg@che.utexas.edu).

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

This work was supported by Grant Nos. 1R01 GM055090 and 1R01 CA154754 from the National Institutes of Health. We also thank B. Iverson for great assistance and guidance, Q. Nguyen for assistance with enzyme assays, J. Lee for assistance with differential scanning fluorimetry, and S. Schaetzle, W. Kelton, M. Pogson, and G. Agnello for helpful discussions and revisions of the manuscript.

## ■ REFERENCES

- (1) Messens, J., and Silver, S. (2006) Arsenate reduction: Thiol cascade chemistry with convergent evolution. *J. Mol. Biol.* 362, 1–17.
- (2) Mukhopadhyay, R., Rosen, B. P., Phung, L. T., and Silver, S. (2002) Microbial arsenic: From geocycles to genes and enzymes. *FEMS Microbiol. Rev.* 26, 311–325.
- (3) Maciaszczyk-Dziubinska, E., Wawrzycka, D., and Wysocki, R. (2012) Arsenic and antimony transporters in eukaryotes. *Int. J. Mol. Sci.* 13, 3527–3548.
- (4) Carlin, A., Shi, W., Dey, S., and Rosen, B. P. (1995) The ars operon of *Escherichia coli* confers arsenical and antimonial resistance. *J. Bacteriol.* 177, 981–986.
- (5) Kruger, M. C., Bertin, P. N., Heipieper, H. J., and Arsène-Ploetze, F. (2013) Bacterial metabolism of environmental arsenic—Mechanisms and biotechnological applications. *Appl. Microbiol. Biotechnol.* 97, 3827–3841.
- (6) Rosen, B. P. (2002) Biochemistry of arsenic detoxification. *FEBS Lett.* 529, 86–92.
- (7) Ji, G., and Silver, S. (1992) Reduction of arsenate to arsenite by the ArsC protein of the arsenic resistance operon of *Staphylococcus aureus* plasmid pI258. *Proc. Natl. Acad. Sci. U.S.A.* 89, 9474–9478.
- (8) Bennett, M. S., Guan, Z., Laurberg, M., and Su, X. D. (2001) *Bacillus subtilis* arsenate reductase is structurally and functionally similar to low molecular weight protein tyrosine phosphatases. *Proc. Natl. Acad. Sci. U.S.A.* 98, 13577–13582.
- (9) Mukhopadhyay, R., Zhou, Y., and Rosen, B. P. (2003) Directed evolution of a yeast arsenate reductase into a protein–tyrosine phosphatase. *J. Biol. Chem.* 278, 24476–24480.
- (10) Liu, J., and Rosen, B. P. (1997) Ligand interactions of the ArsC arsenate reductase. *J. Biol. Chem.* 272, 21084–21089.
- (11) Shi, J., Vlamis-Gardikas, A., Åslund, F., Holmgren, A., and Rosen, B. P. (1999) Reactivity of glutaredoxins 1, 2, and 3 from *Escherichia coli* shows that glutaredoxin 2 is the primary hydrogen donor to ArsC-catalyzed arsenate reduction. *J. Biol. Chem.* 274, 36039–36042.
- (12) DeMel, S., Shi, J., Martin, P., Rosen, B. P., and Edwards, B. F. P. (2004) Arginine 60 in the ArsC arsenate reductase of *E. coli* plasmid R773 determines the chemical nature of the bound As(III) product. *Protein Sci. Publ. Protein Soc.* 13, 2330–2340.
- (13) Bobrowicz, P., Wysocki, R., Owsianik, G., Goffeau, A., and Ulaszewski, S. (1997) Isolation of three contiguous genes, ACRI, ACR2, and ACR3, involved in resistance to arsenic compounds in the yeast *Saccharomyces cerevisiae*. *Yeast (Chichester Engl.)* 13, 819–828.
- (14) Fauman, E. B., Cogswell, J. P., Lovejoy, B., Rocque, W. J., Holmes, W., Montana, V. G., Piwnicka-Worms, H., Rink, M. J., and Saper, M. A. (1998) Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. *Cell* 93, 617–625.
- (15) Li, R., Haile, J. D., and Kennelly, P. J. (2003) An arsenate reductase from *Synechocystis* sp. strain PCC 6803 exhibits a novel combination of catalytic characteristics. *J. Bacteriol.* 185, 6780–6789.
- (16) Stolz, J. F., and Oremland, R. S. (1999) Bacterial respiration of arsenic and selenium. *FEMS Microbiol. Rev.* 23, 615–627.
- (17) Veeravalli, K., Boyd, D., Iverson, B. L., Beckwith, J., and Georgiou, G. (2011) Laboratory evolution of glutathione biosynthesis reveals natural compensatory pathways. *Nat. Chem. Biol.* 7, 101–105.
- (18) Kitagawa, M., Ara, T., Arifuzzaman, M., Ioka-Nakamichi, T., Inamoto, E., Toyonaga, H., and Mori, H. (2006) Complete set of ORF clones of *Escherichia coli* ASKA library (A complete set of *E. coli* K-12 ORF archive): Unique resources for biological research. *DNA Res.* 12, 291–299.
- (19) Patrick, W. M., Quandt, E. M., Swartzlander, D. B., and Matsumura, I. (2007) Multicopy suppression underpins metabolic evolvability. *Mol. Biol. Evol.* 24, 2716–2722.
- (20) Patrick, W. M., and Matsumura, I. (2008) A study in molecular contingency: Glutamine phosphoribosylpyrophosphate amidotransferase is a promiscuous and evolvable phosphoribosylanthranilate isomerase. *J. Mol. Biol.* 377, 323–336.
- (21) Desai, K. K., and Miller, B. G. (2010) Recruitment of genes and enzymes conferring resistance to the nonnatural toxin bromoacetate. *Proc. Natl. Acad. Sci. U.S.A.* 107, 17968–17973.
- (22) Nishida, M., Harada, S., Noguchi, S., Satow, Y., Inoue, H., and Takahashi, K. (1998) Three-dimensional structure of *Escherichia coli* glutathione S-transferase complexed with glutathione sulfonate: Catalytic roles of Cys10 and His106. *J. Mol. Biol.* 281, 135–147.

- (23) Pan, J. L., and Bardwell, J. C. A. (2006) The origami of thioredoxin-like folds. *Protein Sci. Publ. Prot. Soc.* 15, 2217–2227.
- (24) Mössner, E., Huber-Wunderlich, M., and Glockshuber, R. (1998) Characterization of *Escherichia coli* thioredoxin variants mimicking the active-sites of other thiol/disulfide oxidoreductases. *Prot. Sci.* 7, 1233–1244.
- (25) Vetting, M. W., Toro, R., Bhosle, R., Al Obaidi, N. F., Morisco, L. L., Wasserman, S. R., Sojitra, S., Stead, M., Washington, E., Scott Glenn, A., Chowdhury, S., Evans, B., Hammonds, J., Hillerich, B., Love, J., Seidel, R. D., Imker, H. J., Gerlt, J. A., Armstrong, R. N., Almo, S. C., and Enzyme Function Initiative (EFI). (2013) Crystal structure of a glutathione transferase family member from *Salmonella enterica* ty2, target efi-S07262, with bound glutathione. *Be Publ.*
- (26) Kroll, D. A *Visual Method for the Detection of Arsenic 0–500 µg/L*. Hach Company, Loveland, CO.
- (27) Scott, N., Hatlelid, K. M., MacKenzie, N. E., and Carter, D. E. (1993) Reactions of arsenic(III) and arsenic(V) species with glutathione. *Chem. Res. Toxicol.* 6, 102–106.
- (28) Armstrong, R. N. (1991) Glutathione S-transferases: Reaction mechanism, structure, and function. *Chem. Res. Toxicol.* 4, 131–140.
- (29) Griswold, K. E., Aiyappan, N. S., Iverson, B. L., and Georgiou, G. (2006) The evolution of catalytic efficiency and substrate promiscuity in human  $\theta$  class 1–1 glutathione transferase. *J. Mol. Biol.* 364, 400–410.
- (30) Zakharyan, R. A., Sampayo-Reyes, A., Healy, S. M., Tsapralis, G., Board, P. G., Liebler, D. C., and Aposhian, H. V. (2001) Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione S-transferase superfamily. *Chem. Res. Toxicol.* 14, 1051–1057.
- (31) Board, P. G., Coggan, M., Chelvanayagam, G., Easteal, S., Jermini, L. S., Schulte, G. K., Danley, D. E., Hoth, L. R., Griffor, M. C., Kamath, A. V., Rosner, M. H., Chrnyk, B. A., Perregaux, D. E., Gabel, C. A., Geoghegan, K. F., and Pandit, J. (2000) Identification, characterization, and crystal structure of the omega class glutathione transferases. *J. Biol. Chem.* 275, 24798–24806.
- (32) Xia, B., Vlamis-Gardikas, A., Holmgren, A., Wright, P. E., and Dyson, H. J. (2001) Solution structure of *Escherichia coli* glutaredoxin-2 shows similarity to mammalian glutathione S-transferases. *J. Mol. Biol.* 310, 907–918.
- (33) Denton, H., McGregor, J. C., and Coombs, G. H. (2004) Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. *Biochem. J.* 381, 405–412.
- (34) Fyfe, P. K., Westrop, G. D., Silva, A. M., Coombs, G. H., and Hunter, W. N. (2012) Leishmania TDR1 structure, a unique trimeric glutathione transferase capable of deglutathionylation and antimonial prodrug activation. *Proc. Natl. Acad. Sci. U.S.A.* 109, 11693–11698.
- (35) Rife, C. L., Parsons, J. F., Xiao, G., Gilliland, G. L., and Armstrong, R. N. (2003) Conserved structural elements in glutathione transferase homologues encoded in the genome of *Escherichia coli*. *Proteins* 53, 777–782.
- (36) Sheehan, D., Meade, G., Foley, V. M., and Dowd, C. A. (2001) Structure, function, and evolution of glutathione transferases: Implications for classification of non-mammalian members of an ancient enzyme superfamily. *Biochem. J.* 360, 1–16.
- (37) Neidhardt, F. C., Bloch, P. L., and Smith, D. F. (1974) Culture medium for Enterobacteria. *J. Bacteriol.* 119, 736–747.
- (38) Datsenko, K. A., and Wanner, B. L. (2000) One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. U.S.A.* 97, 6640–6645.
- (39) Miller, J. (1972) *Experiments in Molecular Genetics*. Cold Spring Harbor Laboratory Press, Plainview, NY.
- (40) Baba, T., Ara, T., Hasegawa, M., Takai, Y., Okumura, Y., Baba, M., Datsenko, K. A., Tomita, M., Wanner, B. L., and Mori, H. (2006) Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: The Keio collection. *Mol. Syst. Biol.* 2, 2006–0008.